Remember to assess the 'whole' patient: a further immune-related adverse event of programmed cell death 1 checkpoint inhibition

Affiliations

Comment

H J A Hunter. Br J Dermatol. 2020 Feb.

. 2020 Feb;182(2):276-277.

doi: 10.1111/bjd.18716. Epub 2019 Dec 18.

¹ The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.

No abstract available

Comment on

Acquired generalized lipodystrophy under immune checkpoint inhibition.
Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J; PATIO group. Haddad N, et al. Br J Dermatol. 2020 Feb;182(2):477-480. doi: 10.1111/bjd.18124. Epub 2019 Aug 9. Br J Dermatol. 2020. PMID: 31077337

1. Bridge JA, Lee JC, Daud A et al. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front Med (Lausanne) 2018; 5:34.
1. Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol 2019; https://doi.org/10.1016/j.semcancer.2019.06.012
1. Hwang SJ, Carlos G, Wakade D et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74:455-61.e1.
1. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19:345-61.
1. Haddad N, Vidal-Trecan T, Baroudjian B et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol 2020; 182:477-80.